Genentech Terminates IDO Inhibitor Partnership with NewLink

Genentech, a member of the Roche Group, has terminated its four-year-old collaboration with NewLink Genetics to discover next-generation combination IDO-TDO (indoleamine-pyrrole 2,3-dioxygenase–tryptophan-2,3-dioxygenase) therapy compounds, nearly a year after the Roche subsidiary returned to NewLink rights to the cancer candidate GDC-0919 (navoximod).The collaboration had been expected to generate more than $1.15 billion for NewLink when launched in October 2014 , with Genentech paying Ne